CD274 and cervical carcinoma: Tremelimumab (fully human monoclonal antibody against CTLA-4) plus durvalumab (anti-PD-L1 antibody) combined with metronomic oral vinorelbine in recurrent cervical cancer was investigated in the multi-cohort phase I/II MOVIE trial.